纳米疗法重塑瘤微环境:前列腺癌治疗的新策略
Juan Deng1,2, Shaofei Yuan1, Wenjie Pan1
1The Third Affiliated Hospital of Wenzhou Medical university, Wenzhou, 325200, China.
ACS omega
|July 1, 2024
概括
新型纳米疗法策略为前列腺癌 (PCa) 治疗提供了新的希望,通过向瘤微环境 (TME) 来治疗. 这种方法旨在克服激素耐药性,并改善患者对这种广泛传播的癌症的治疗结果.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 癌症生物学 癌症生物学
背景情况:
- 前列腺癌 (PCa) 是男性的全球领先癌症.
- 雄激素剥夺疗法 (ADT) 是标准的,但激素抵抗导致预后不佳.
- 瘤微环境 (TME) 越来越被认为是PCa进展和治疗耐药性的关键因素.
研究的目的:
- 审查PCa TME的特征和传统治疗的副作用.
- 为突出PCa.新兴的纳米治疗策略.
- 讨论纳米疗法的治疗机制和TME影响.
主要方法:
- 对PCa TME特征的文献综述.
- 传统PCa治疗副作用的审查.
- 分析目前纳米疗法方法,机制和TME在PCa的影响.
主要成果:
- 已建立的PCa TME特征和ADT限制是详细的.
- 新型纳米疗法策略显示了针对PCa TME的潜力.
- 纳米疗法在克服治疗耐药性和提高治疗疗效方面表现有前途.
结论:
- 纳米疗法为克服前列腺癌中ADT耐药性的前沿提供了一个有希望的前沿.
- 了解TME相互作用是开发有效纳米医学策略的关键.
- 预计进一步的研究将加速PCa纳米治疗的临床应用.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.3K
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
